HAI Book 2025 - Flipbook - Page 686
Chan, Tevy
168
Clinical validation of the Lumipulse G1200 automated immunoassay
for the measurement of Alzheimer9s disease plasma biomarkers
Tevy Chan1, Nesrine Rahmouni1, Yansheng Zheng1, Marina Congalves1, Arthur Macedo1,
Etienne Aumont1, Joseph Therriault1, Brandon Hall1, Yi-Ting Wang1, Lydia Trudel1, Stijn
Servaes1, Jaime Fernandez-Arias1, Robert Hopewell1,2, Henrik Zetterberg3, Tharick Pascoal4,
Andrea Benedet3, Pedro Rosa-Neto1,2
1
Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Montréal, QC,
Canada, Montreal, QC, CA
2
McConnell Brain Imaging Center, McGill University, Montreal, QC, CA
3
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska
Academy, University of Gothenburg, Sweden, Gothenburg, SE
4
University of Pittsburg, Pittsburg, PA, US
Introduction: Recent advances in plasma biomarkers have positioned them as promising diagnostic tools for
Alzheimer9s disease (AD). Lumipulse G1200 (Fujirebio) is a fully automated immunoassay instrument that simplifies
the analysis of these biomarkers. Here, we evaluated the diagnostic performance of the Lumipulse G1200 plasma
phosphorylated tau(p-tau)181 and p-tau217 immunoassays in detecting AD pathology.
Methods: Plasma samples of 102 participants from the TRIAD cohort (median age 67 years, 54% female) were
analysed. Spearman9s correlation examined the association between plasma p-tau181 and p-tau217 with A´
([18F]NAV4694) and tau ([18F]MK6240) PET. Discriminative performance for A´ and tau PET status was assessed
using the area under the curve (AUC) of Receiver operating Characteristic (ROC) analysis.
Results: Plasma p-tau181 and p-tau217 were significantly higher in individuals with clinical diagnosis of AD
compared to the cognitively normal or mild cognitive impairment not due to AD (Fig.1). Plasma p-tau217 very
strongly correlated with both A´ and tau PET SUVR (ρ=0.805 and 0.797 respectively, p-value
